On this episode of Stock Movers:
- Eli Lilly (LLY) said Monday it expects its highly anticipated weight-loss pill to receive US regulatory approval as early as the second quarter of 2026, slightly later than it signaled earlier. Drugmakers believe weight-loss pills could expand the market for popular GLP-1 medicines, which up until earlier this year were only sold as injections. In December, Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from Lilly.
- Shake Shack (SHAK) shares slipped after the burger chain reported preliminary fourth-quarter sales below Wall Street estimates. Preliminary revenue was $400.5 million, below the $409 million average estimate of analysts surveyed by Bloomberg, with Shake Shack blaming inclement weather for keeping diners away. Shake Shack expects sales to expand by low-single digits in 2026, compared with analyst expectations for 2.4% growth, and plans to open 95 to 105 company-operated and licensed locations this year.
- Abercrombie & Fitch (ANF) shares sank after holiday sales disappointed investors, helping spark a selloff in retail stocks. The company now expects fourth-quarter sales growth of around 5%, the mid-point of its prior range, and didn’t raise its outlook. Shares of Abercrombie plummeted 18% on Monday, while American Eagle and Urban Outfitters also sank after their holiday results underwhelmed Wall Street.
See omnystudio.com/listener for privacy information.
